Sarabjot Pabla’s Post

Discover the groundbreaking potential of HER2-CD3-Fc bispecific antibody-encoding mRNA delivered by lipid nanoparticles in suppressing HER2-positive tumor growth. Our latest publication highlights the robust expression and potent T cell cytotoxicity induced by HER2-CD3-Fc mRNA-LNPs, demonstrating a promising therapeutic approach for treating HER2-positive cancer. Learn more about this innovative therapy by reading our full study here: https://hubs.li/Q02KrwZJ0

Please join on discussion of bispecific antibody discovery. How structure and function drives novel MOA

Worldwide there are an estimated 1.8 million new cases of non-small cell lung cancer (NSCLC) each year and BeiGene continues to share new research for this patient population. New research published in ESMO Open (a journal from ESMO - European Society for Medical Oncology) highlights results from the final analysis of a Phase 3 study evaluating our PD-1 inhibitor in patients with advanced nonsquamous NSCLC. Read the research here: https://bit.ly/3TSmYLs

Last week, our CEO Ben Zeskind, Ph.D. sat down with Caroline Hopkins at Precision Oncology News, to discuss the recent progress with our lead product candidate, IMM-1-104. From IMM-1-104's fast-track designation for patients with pancreatic cancer who have failed one line of treatment, to dosing our first patient in the Phase 2 portion of the ongoing IMM-1-104 Phase 1/2a clinical trial, to reporting positive preliminary data from the Phase 1 portion of that trial Read more about our differentiated approach to cancer research and next steps with IMM-1-104.https://buff.ly/4cvtRd2

Brilliantly designed I-SPY2 trial - adaptive neoadjuvant treatments for early breast cancer, stratified by receptor status, DNA repair deficiency & immunogenicity and tailored according to predicted response. The ADC/IO synergy continues to grow & this trial could really set the platform for personalised de-escalation & intensification approaches. Great abstract at #ESMO24. https://lnkd.in/egvFU62r ESMO - European Society for Medical Oncology

SE-9 is a novel dual-targeting SOS1/EGFR inhibitor that represents a promising treatment strategy for prostate cancer. Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/gs3rA47M #SE-9 #SOS1/EGFR #dual-targetinginhibitor #prostatecancer #buildingblocks

💡Get inspired❗️ In the #FF4EuroHPC experiment, #SME utilize #HPC to develop AÏDA innovative solution to address breast cancer treatment. It predicts the efficacy of different cancer drugs for each individual patient, based on their biopsy readings. Learn more ▶️ https://lnkd.in/dkN_6idy Chosa Oncology JADBio AutoML Hellenic Mediterranean University #successstory #technology #medicine #cancertreatment

Newly released Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage #BreastCancer: ASCO Guideline Update for women with early-stage invasive HR pos, HER2 neg #breastcancer. Learn more from the Journal of Clinical Oncology's ASCO Guideline Update!

#ASCO 2024 - Abstract 5550: Phase 1b/2a Study of BAT8006, a Folate Receptor α Antibody Drug Conjugate with Strong Bystander Effect, in Subjects with Advanced Solid Tumors --- poster download available at https://lnkd.in/ekyMFZUt #ASCO2024 #ADC #ovariancancer #oncology #cancer #ASCO24

ROS1, a key biomarker in oncology clinical studies, holds significant importance as it aids in identifying a specific subset of cancer patients who may benefit from targeted therapies. Understanding the presence of ROS1 alterations allows for more precise treatment strategies, paving the way for improved outcomes and a step forward in personalized cancer care. In the realm of oncology research, unraveling the role of ROS1 contributes to unlocking tailored therapeutic approaches for patients with these genetic alterations. #ROS1 #OncologyResearch #PrecisionMedicine